An Open-Label, Phase II Study to Evaluate the Biological Activity of Cediranib (AZD2171) as Measured by [F 18] Fluoro 2 Deoxy D Glucose - Positron Emission Tomography (FDG-PET) Response, in Patients With Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intolerant to Imatinib Mesylate.

Trial Profile

An Open-Label, Phase II Study to Evaluate the Biological Activity of Cediranib (AZD2171) as Measured by [F 18] Fluoro 2 Deoxy D Glucose - Positron Emission Tomography (FDG-PET) Response, in Patients With Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intolerant to Imatinib Mesylate.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2012

At a glance

  • Drugs Cediranib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Mar 2011 Actual patient number changed from 38 to 35 as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Actual end date (Dec 2009) and actual number of patients (38) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Planned end date changed from 1 Dec 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top